Goldman Sachs
FENC icon

Goldman Sachs’s Fennec Pharmaceuticals FENC Stock Holding History

Goldman Sachs’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$360K Sell
33,452
-22,212
-40% -$181K ﹤0.01% 5902
2026
Q1 		$342K Buy
55,664
+12,075
+28% +$93.2K ﹤0.01% 5822
2025
Q4 		$336K Buy
43,589
+17,099
+65% +$140K ﹤0.01% 5809
2025
Q3 		$248K Buy
26,490
+10,552
+66% +$91.3K ﹤0.01% 5857
2025
Q2 		$132K Sell
15,938
-27,282
-63% -$187K ﹤0.01% 5762
2025
Q1 		$263K Sell
43,220
-27,977
-39% -$180K ﹤0.01% 5522
2024
Q4 		$450K Buy
71,197
+17,444
+32% +$89.4K ﹤0.01% 5300
2024
Q3 		$269K Buy
53,753
+33,619
+167% +$194K ﹤0.01% 5350
2024
Q2 		$123K Sell
20,134
-22,957
-53% -$191K ﹤0.01% 5377
2024
Q1 		$479K Buy
43,091
+12,091
+39% +$121K ﹤0.01% 4768
2023
Q4 		$348K Buy
31,000
+13,664
+79% +$113K ﹤0.01% 4924
2023
Q3 		$130K Sell
17,336
-13,496
-44% -$110K ﹤0.01% 5137
2023
Q2 		$272K Buy
30,832
+10,081
+49% +$83.8K ﹤0.01% 5058
2023
Q1 		$173K Sell
20,751
-234
-1% -$2.17K ﹤0.01% 5345
2022
Q4 		$201K Buy
+20,985
New +$186K ﹤0.01% 5305
2022
Q3 		– Sell
-10,029
Closed -$56K – 6353
2022
Q2 		$56K Sell
10,029
-3,051
-23% -$17.7K ﹤0.01% 6008
2022
Q1 		$73K Sell
13,080
-368
-3% -$1.85K ﹤0.01% 6189
2021
Q4 		$59K Buy
13,448
+16
+0.1% +$119 ﹤0.01% 6233
2021
Q3 		$127K Buy
13,432
+34
+0.3% +$255 ﹤0.01% 5866
2021
Q2 		$98K Sell
13,398
-7,659
-36% -$51.1K ﹤0.01% 5953
2021
Q1 		$131K Sell
21,057
-3,614
-15% -$27.2K ﹤0.01% 5770
2020
Q4 		$184K Sell
24,671
-129
-0.5% -$982 ﹤0.01% 5121
2020
Q3 		$150K Sell
24,800
-5,761
-19% -$40.6K ﹤0.01% 5004
2020
Q2 		$255K Buy
30,561
+16,337
+115% +$121K ﹤0.01% 4696
2020
Q1 		$84K Hold
14,224
– – ﹤0.01% 4970
2019
Q4 		$92K Buy
+14,224
New +$76.4K ﹤0.01% 5051
2018
Q4 		– Sell
-10,438
Closed -$86K – 5369
2018
Q3 		$86K Sell
10,438
-6,552
-39% -$60.8K ﹤0.01% 5183
2018
Q2 		$177K Sell
16,990
-1,008
-6% -$11.9K ﹤0.01% 5026
2018
Q1 		$218K Buy
+17,998
New +$170K ﹤0.01% 4958

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCA
Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Goldman Sachs's FENC Position: Q2 2026 in Review

Goldman Sachs reduced its Fennec Pharmaceuticals (FENC) stake by 40% in Q2 2026, selling an estimated $181K and leaving 33,452 shares worth $360K. The position accounts for ﹤0.01% of the portfolio, ranked #5902.

Goldman Sachs first reported a position in FENC in Q1 2018 and has held it in 29 quarters since. The position peaked at $479K in Q1 2024. 104 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • Goldman Sachs held 33,452 shares of Fennec Pharmaceuticals worth $360K as of Q2 2026.
  • Goldman Sachs sold 22,212 Fennec Pharmaceuticals shares in Q2 2026, an estimated $181K.
  • Fennec Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5902 holding.
  • Goldman Sachs first reported a position in Fennec Pharmaceuticals in Q1 2018 and has held it in 29 quarters since.
  • Goldman Sachs's Fennec Pharmaceuticals position peaked at $479K in Q1 2024.
  • 104 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.